| Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy (NCT05640713) | Henan Cancer Hospital | 2022-12-01 |
| Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence (NCT05545124) | Henan Cancer Hospital | 2022-11-01 |
| A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer (NCT05394285) | Henan Cancer Hospital | 2022-09-21 |
| Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NCT05547737) | Henan Cancer Hospital | 2022-09-21 |
| Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor (NCT05490667) | Henan Cancer Hospital | 2022-08-20 |
| Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer (NCT05398861) | Henan Cancer Hospital | 2022-08-19 |
| Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (NCT05490485) | Henan Cancer Hospital | 2022-08-05 |
| Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors (NCT05468970) | Henan Cancer Hospital | 2022-08-03 |
| Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT05495152) | Henan Cancer Hospital | 2022-08-01 |
| A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients (NCT05442138) | Henan Cancer Hospital | 2022-08-01 |
| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (NCT05377658) | Henan Cancer Hospital | 2022-07-26 |
| Study on Clinical Features, Treatment Mode and Survival of Sarcoma (NCT05453409) | Henan Cancer Hospital | 2022-06-07 |
| Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma (NCT05276167) | Henan Cancer Hospital | 2022-06-06 |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) (NCT05328440) | Henan Cancer Hospital | 2022-05-20 |
| Camrelizumab Combined With Apatinib Mesylate (NCT05380986) | Henan Cancer Hospital | 2022-05-20 |
| Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure (NCT05335473) | Henan Cancer Hospital | 2022-05-13 |
| Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer (NCT05177068) | Henan Cancer Hospital | 2022-05-13 |
| A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer (NCT05474690) | Henan Cancer Hospital | 2022-05-11 |
| RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer (NCT05313906) | Henan Cancer Hospital | 2022-05-07 |
| A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab (NCT05583383) | Henan Cancer Hospital | 2022-03-31 |
| Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer (NCT05296577) | Henan Cancer Hospital | 2022-03-22 |
| Cryoablation for Advanced Bone and Soft Tissue Tumors (NCT05615545) | Henan Cancer Hospital | 2022-03-10 |
| An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC (NCT05252091) | Henan Cancer Hospital | 2022-02-20 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (NCT05083208) | Henan Cancer Hospital | 2022-02-20 |
| Anti-emetic Prophylaxis With or Without Dexamethasone (NCT05242874) | Henan Cancer Hospital | 2022-02-01 |
| Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. (NCT05189483) | Henan Cancer Hospital | 2022-01-01 |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. (NCT05207735) | Henan Cancer Hospital | 2022-01-01 |
| Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma (NCT05209620) | Henan Cancer Hospital | 2021-12-21 |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer (NCT05176080) | Henan Cancer Hospital | 2021-12-08 |
| Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer (NCT05063136) | Henan Cancer Hospital | 2021-09-28 |
| Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer (NCT05299255) | Henan Cancer Hospital | 2021-09-05 |
| TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. (NCT05013697) | Henan Cancer Hospital | 2021-09-01 |
| Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer (NCT05023720) | Henan Cancer Hospital | 2021-07-20 |
| Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (NCT04901754) | Henan Cancer Hospital | 2021-07-14 |
| Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy (NCT05282563) | Henan Cancer Hospital | 2021-07-01 |
| Toripalimab Plus FLOT in Locally Advanced Gastric Cancer (NCT04891016) | Henan Cancer Hospital | 2021-06-25 |
| Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma (NCT04938297) | Henan Cancer Hospital | 2021-05-26 |
| Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (NCT04660097) | Henan Cancer Hospital | 2021-05-20 |
| TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma (NCT04891900) | Henan Cancer Hospital | 2021-05-10 |
| Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma (NCT05747521) | Henan Cancer Hospital | 2021-04-29 |
| Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma (NCT04948125) | Henan Cancer Hospital | 2021-04-28 |
| Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (NCT04681287) | Henan Cancer Hospital | 2021-04-23 |
| A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) (NCT04778800) | Henan Cancer Hospital | 2021-03-20 |
| Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma (NCT04737889) | Henan Cancer Hospital | 2021-01-13 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer (NCT04553939) | Henan Cancer Hospital | 2021-01-04 |
| Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma (NCT05569668) | Henan Cancer Hospital | 2021-01-01 |
| Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04668365) | Henan Cancer Hospital | 2020-12-25 |
| A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors (NCT04615312) | Henan Cancer Hospital | 2020-11-14 |
| A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (NCT04547907) | Henan Cancer Hospital | 2020-09-18 |
| GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel (NCT04538833) | Henan Cancer Hospital | 2020-09-09 |
| Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer (NCT04675866) | Henan Cancer Hospital | 2020-08-17 |
| Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma (NCT04280822) | Henan Cancer Hospital | 2020-04-21 |
| Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients (NCT04199520) | Henan Cancer Hospital | 2020-04-15 |
| Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC (NCT04331626) | Henan Cancer Hospital | 2020-04-01 |
| Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (NCT04293276) | Henan Cancer Hospital | 2020-04-01 |
| SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma (NCT03950271) | Henan Cancer Hospital | 2020-01-20 |
| R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04214626) | Henan Cancer Hospital | 2020-01-05 |
| SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer (NCT04213898) | Henan Cancer Hospital | 2020-01-01 |
| Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT04229849) | Henan Cancer Hospital | 2020-01-01 |
| Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer (NCT04199559) | Henan Cancer Hospital | 2019-12-01 |
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (NCT04138212) | Henan Cancer Hospital | 2019-10-22 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. (NCT04063683) | Henan Cancer Hospital | 2019-10-07 |
| Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC (NCT04055792) | Henan Cancer Hospital | 2019-09-11 |
| An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment (NCT04087252) | Henan Cancer Hospital | 2019-09-04 |
| Study of CT and MR in the Gastric Cancer (NCT04028375) | Henan Cancer Hospital | 2019-09-01 |
| Study of CT and MR in the Lung Cancer (NCT04034667) | Henan Cancer Hospital | 2019-09-01 |
| Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer (NCT03942068) | Henan Cancer Hospital | 2019-09-01 |
| Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (NCT04067037) | Henan Cancer Hospital | 2019-08-26 |
| PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma (NCT04341857) | Henan Cancer Hospital | 2019-07-30 |
| Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma (NCT03939962) | Henan Cancer Hospital | 2019-07-24 |
| Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule (NCT04223583) | Henan Cancer Hospital | 2019-06-26 |
| Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer (NCT03983759) | Henan Cancer Hospital | 2019-06-20 |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma (NCT03986515) | Henan Cancer Hospital | 2019-06-04 |
| Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type (NCT03963193) | Henan Cancer Hospital | 2019-06-01 |
| Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer (NCT03954756) | Henan Cancer Hospital | 2019-06-01 |
| Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol (NCT03977077) | Henan Cancer Hospital | 2019-06-01 |
| Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody (NCT03975036) | Henan Cancer Hospital | 2019-04-08 |
| Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies (NCT03881774) | Henan Cancer Hospital | 2019-02-27 |
| SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer (NCT03755115) | Henan Cancer Hospital | 2019-02-01 |
| CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma (NCT03881761) | Henan Cancer Hospital | 2019-02-01 |
| Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma (NCT04263935) | Henan Cancer Hospital | 2019-01-03 |
| Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC (NCT04664972) | Henan Cancer Hospital | 2018-11-23 |
| A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer (NCT03691051) | Henan Cancer Hospital | 2018-11-20 |
| A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma (NCT03735511) | Henan Cancer Hospital | 2018-11-20 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. (NCT03735966) | Henan Cancer Hospital | 2018-11-20 |
| the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (NCT04430361) | Henan Cancer Hospital | 2018-09-07 |
| The Application of 3T MRI in Esophageal Cancer (NCT03635619) | Henan Cancer Hospital | 2018-09-02 |
| Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma (NCT03540303) | Henan Cancer Hospital | 2018-04-12 |
| BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma (NCT03664661) | Henan Cancer Hospital | 2018-04-11 |
| The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal (NCT03451942) | Henan Cancer Hospital | 2018-02-05 |
| Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma (NCT03413436) | Henan Cancer Hospital | 2018-01-31 |
| Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer (NCT03397199) | Henan Cancer Hospital | 2018-01-09 |
| Study of BCMA CAR-T in Multiple Myeloma (NCT03322735) | Henan Cancer Hospital | 2017-12-08 |
| Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer (NCT03389087) | Henan Cancer Hospital | 2017-11-29 |
| Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma (NCT03383237) | Henan Cancer Hospital | 2017-11-29 |
| Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma (NCT03376737) | Henan Cancer Hospital | 2017-10-12 |